A5019090648- Schizophrenia research and treatment
- Treatment of Major Depression
- Receptor Mechanisms and Signaling
- Neurological disorders and treatments
- Bipolar Disorder and Treatment
- Dementia and Cognitive Impairment Research
- Vagus Nerve Stimulation Research
- Mental Health Research Topics
- Neuroscience and Neuropharmacology Research
- Alzheimer's disease research and treatments
- Tryptophan and brain disorders
- Neurotransmitter Receptor Influence on Behavior
- Health Systems, Economic Evaluations, Quality of Life
- Mental Health and Psychiatry
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Functional Brain Connectivity Studies
- Ion channel regulation and function
- Cholinesterase and Neurodegenerative Diseases
- Epilepsy research and treatment
- Bioinformatics and Genomic Networks
- Neuroscience and Neural Engineering
- Computational Drug Discovery Methods
- Electroconvulsive Therapy Studies
- Psychosomatic Disorders and Their Treatments
- Attention Deficit Hyperactivity Disorder
Bristol-Myers Squibb (United States)
2024-2025
Johnson & Johnson (United States)
2025
Janssen (Belgium)
2025
Janssen (United States)
2025
University of Miami
2024
Bristol-Myers Squibb (Germany)
2024
Duke University
2024
University of Nebraska Medical Center
2020-2023
Takeda (United States)
2009-2019
Deerfield (United States)
2009-2019
Theories of human behavior from Plato to Freud have repeatedly emphasized links between emotion and reason, a relationship now commonly attributed pathways connecting phylogenetically "old" "new" brain regions. Expanding on this theory, study examined functional interactions specific limbic neocortical regions accompanying normal disease-associated shifts in negative mood state.Regions concordant change provocation transient sadness healthy volunteers resolution chronic dysphoric symptoms...
THE relationship between pretreatment regional cerebral glucose metabolism and eventual antidepressant drug response was measured using positron emission tomography (PET) in hospitalized patients with unipolar depression. Rostral anterior cingulate uniquely differentiated treatment responders from non-responders. Hypometabolism characterized non-responders when compared controls, contrast to who were hypermetabolic. Metabolism no other region discriminated the two groups, nor did associated...
This journal offers reviews of key neuropsychiatric topics for clinicians, with the aim tying research findings to needs clinical practice. It strives "unite theory, findings, and therapies in cohesive, comprehensive presentations." The first three issues we examined did contain important, timely, interesting that included advances neuroimaging, syndromes developmentally disabled, brain damage legal responsibility. Each issue includes a brief introduction from editor, followed by few pages...
The muscarinic receptor agonist xanomeline has antipsychotic properties and is devoid of dopamine receptor–blocking activity but causes cholinergic adverse events. Trospium a peripherally restricted antagonist that reduces peripheral effects xanomeline. efficacy safety combined trospium in patients with schizophrenia are unknown.
Importance A significant need exists for new antipsychotic medications with different mechanisms of action, greater efficacy, and better tolerability than existing agents. Xanomeline is a dual M 1 /M 4 preferring muscarinic receptor agonist no direct D 2 dopamine blocking activity. KarXT combines xanomeline the peripheral antagonist trospium chloride goal reducing adverse events due to xanomeline-related activation. In prior trials, xanomeline-trospium was effective in symptoms psychosis...
Abstract The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials Alzheimer’s disease and schizophrenia. We present data on the effect of KarXT (xanomeline–trospium) schizophrenia from 5-week, randomised, double-blind, placebo-controlled EMERGENT-1 trial (NCT03697252). Analyses included 125 patients with computerised Cogstate Brief Battery (CBB) subtest scores at baseline endpoint. A post hoc subgroup analysis evaluated effects cognitive performance or without...
KarXT combines xanomeline, an M1/M4 preferring muscarinic agonist with no direct D2 receptor antagonism, the peripherally restricted anticholinergic trospium. In EMERGENT-1 (NCT03697252), a 5-week, randomized, double-blind, placebo-controlled, phase 2 study in inpatients schizophrenia, met primary efficacy endpoint, numerous secondary endpoints, and was generally well tolerated. Here, we conducted additional post hoc analyses of safety tolerability data from particular focus on adverse...
Objective: To evaluate Positive and Negative Syndrome Scale (PANSS) categorical response rates, time course of response, symptom subdomains with the combination oral agent KarXT (xanomeline-trospium) in treatment schizophrenia.Methods: Post hoc analysis was conducted for EMERGENT-1 (NCT03697252), a 5-week, inpatient, placebo-controlled, phase 2 study acute psychosis patients who met DSM-5 criteria schizophrenia. The between September 2018 August 2019. Categorical thresholds used were PANSS...
Abstract Rationale The M 1 /M 4 preferring muscarinic receptor agonist xanomeline demonstrated antipsychotic and procognitive effects in patients with Alzheimer’s disease or schizophrenia prior studies, but further clinical development was limited by cholinergic adverse events (AEs). KarXT combines the peripherally restricted antagonist trospium goal of improving tolerability is for other neuropsychiatric disorders. Objective Test hypothesis that can mitigate AEs associated xanomeline....
Article AbstractObjective: The onset or worsening of sexual dysfunction is a common treatment-emergent side effect antidepressant medications. Post hoc analyses pooled data from placebo-controlled studies were utilized to assess functioning in patients receiving duloxetine paroxetine. Method: Acute-phase obtained four 8-week, double-blind, placebo- and paroxetine-controlled trials similar design which meeting DSM-IV criteria for major depressive disorder randomly assigned receive placebo (N...
This study characterized the durability of improvement in patients who responded early or late while receiving vagus nerve stimulation (VNS). In both a pilot and pivotal study, were identified had at least 50% reduction symptom scores 3 months (early responders) 12 (late after starting VNS. Probabilities determined for maintenance response 12-month 24-month time-points. Consistency throughout period was evaluated, testing change serial depression ratings. 30.5%, 23.7% 45.8% responders, later...
In the 5-week, randomized, double-blind, placebo-controlled EMERGENT-1 (NCT03697252), EMERGENT-2 (NCT04659161), and EMERGENT-3 (NCT04738123) trials, xanomeline trospium chloride (formerly known as KarXT) significantly improved symptoms of schizophrenia was generally well tolerated. We pooled data from EMERGENT trials to further characterize efficacy xanomeline/trospium provide sufficient statistical power analyze responses in participant subgroups. analyses, Positive Negative Syndrome Scale...